Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDPP4HTR1BHTR1D
The experimentally established mechanism targets of Benzoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.70 |
| ▸ | DAO | P14920 | 1/20 | 0.70 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.70 |
| ▸ | CES1 | P23141 | 4/20 | 0.58 |
| ▸ | CES2 | O00748 | 3/20 | 0.58 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.50 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.50 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzoic Acid SCHEMBL2762545 | 0.98 | TSHR (0.67) | TSHRDAONAPRTCES1CES2 | |
| Benzoic Acid SCHEMBL28196696 | 0.93 | TSHR (0.61) | TSHRDAONAPRTCES1CES2 | |
| Terephthalic Acid SCHEMBL10582137 | 0.90 | TSHR (0.67) | TSHRDAONAPRTCES1CES2 | |
| Benzoic Acid SCHEMBL31376992 | 0.90 | TSHR (0.78) | TSHRDAONAPRTCES1CES2 | |
| Benzoic Acid SCHEMBL10952729 | 0.87 | TSHR (0.74) | TSHRDAONAPRTCES1CES2 | |
| Benzoic Acid SCHEMBL11767340 | 0.87 | TSHR (0.74) | TSHRDAONAPRTCES1CES2 | |
| Benzoic Acid SCHEMBL30599484 | 0.87 | TSHR (0.74) | TSHRDAONAPRTCES1CES2 | |
| Benzoic Acid SCHEMBL8653124 | 0.86 | TSHR (0.64) | TSHRDAONAPRTCES1CES2 | |
| Benzophenone SCHEMBL2724412 | 0.85 | ALDH1A1 (0.70) | TSHRCES1SRD5A2CYP3A4MAPT | |
| Benzoic Acid SCHEMBL11455168 | 0.85 | TSHR (0.70) | TSHRDAONAPRTCES1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170224637-A1 | INTRANSAL DELIVERY OF CURCUMIN | DePuy Synthes Products, Inc. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20160374960-A1 | Method of Topically Administering a Curcumin Derivative | JOHNSON & JOHNSON CONSUMER, INC. | 2016-12-29 | — | — | US | disclosed |
| EP-2749552-B1 | Curcumin-resveratrol hybrids | CODMAN & SHURTLEFF (US) | 2015-11-18 | — | — | EP | disclosed |
| EP-2749552-A1 | Curcumin-resveratrol hybrids | Codman & Shurtleff, Inc. (US) | 2014-07-02 | — | — | EP | disclosed |
| US-20140163116-A1 | METHOD OF TREATING CANCER USING A CURCUMIN DERIVATIVE | DePuy Synthes Products, LLC (US) | 2014-06-12 | — | — | US | disclosed |
| US-8609652-B2 | Method of administering a methylene blue-curcumin analog for the treatment of alzheimer's disease | DePuy Synthes Products, LLC (US) | 2013-12-17 | — | — | US | disclosed |
| US-20130150628-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A CURCUMIN DERIVATIVE | DIMAURO THOMAS M (US) | 2013-06-13 | — | — | US | disclosed |
| US-8383865-B2 | Curcumin derivatives | CODMAN & SHURTLEFF, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8350093-B2 | Methylated curcumin-resveratrol hybrid molecules for treating cancer | CODMAN & SHURTLEFF, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8288444-B2 | Iontophoretic delivery of curcumin and curcumin analogs for the treatment of Alzheimer's disease | CODMAN & SHURTLEFF, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-7723515-B1 | Methylene blue—curcumin analog for the treatment of alzheimer's disease | CODMAN & SHURTLEFF, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20100087527-A1 | Curcumin Derivatives | CODMAN & SHURTLEFF, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20090326275-A1 | USE OF NITROGEN-CONTAINING CURCUMIN ANALOGS FOR THE TREATMENT OF ALZHEIMERS DISEASE | DEPUY SPINE, LLC | 2009-12-31 | — | — | US | disclosed |
| US-20090325963-A1 | Iontophoretic Delivery of Curcumin and Curcumin Analogs for the Treatment of Alzheimer's Disease | CODMAN & SHURTLEFF, INC. | 2009-12-31 | — | — | US | disclosed |
| WO-2009158407-A1 | IONTOPHORETIC DELIVERY OF CURCUMIN AND CURCUMIN ANALOGS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | CODMAN & SHURTLEFF, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| EP-2136797-A2 | INTRANASALLY ADMINISTERING CURCUMIN IN A BOLUS OF HELIUM GAS TO TREAT ALZHEIMER'S DISEASE | Codman & Shurtleff Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090087385-A1 | Intranasally administering curcumin in a bolus of helium gas to treat alzheimers disease | CODMAN & SHURTLEFF, INC. | 2009-04-02 | — | — | US | disclosed |
| WO-2008131059-A2 | INTRANASALLY ADMINISTERING CURCUMIN IN A BOLUS OF HELIUM GAS TO TREAT ALZHEIMER'S DISEASE | CODMAN & SHURTLEFF, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080076821-A1 | INTRANASALLY ADMINISTERING CURCUMIN PRODRUGS TO THE BRAIN TO TREAT ALZHEIMER'S DISEASE | DePuy Synthes Products, Inc. | 2008-03-27 | — | — | US | disclosed |
| US-6048875-A | CARDIOVASCULAR DISORDERS; REDUCING THROMBOSIS | ADIR ET COMPAGNIE (FR) | 2000-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160374960-A1 | Method of Topically Administering a Curcumin Derivative | S100A11, S100A4, S100A6 | TSHR 4856/4885DAO 3615/4885NAPRT 484/4885 |
| US-20090326275-A1 | USE OF NITROGEN-CONTAINING CURCUMIN ANALOGS FOR THE TREATMENT OF ALZHEIMERS DISEASE | SLC1A3, SLC1A1, SLC1A2 | TSHR 4271/4885DAO 828/4885NAPRT 162/4885 |
| US-20130150628-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A CURCUMIN DERIVATIVE | CPT1A, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ABCB1 | TSHR 4838/4885DAO 4874/4885NAPRT 2329/4885 |
| US-20140163116-A1 | METHOD OF TREATING CANCER USING A CURCUMIN DERIVATIVE | HDAC5, HDAC6, CPT1A | TSHR 4641/4885DAO 4589/4885NAPRT 1569/4885 |
| US-20170224637-A1 | INTRANSAL DELIVERY OF CURCUMIN | FABP7, FABP2, NDUFB5 | TSHR 4027/4885DAO 4668/4885NAPRT 93/4885 |
| US-20100087527-A1 | Curcumin Derivatives | CPT1A, S100A10, PKD1 | TSHR 4680/4885DAO 4539/4885NAPRT 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.